Nacuity Pharmaceuticals Announces Positive Data from Clinical Trial Evaluating NPI-001 to Treat Retinitis Pigmentosa Associated with Usher Syndrome
Nacuity Pharmaceuticals Announces Positive Data from Clinical Trial Evaluating NPI-001 to Treat Retinitis Pigmentosa Associated with Usher Syndrome GlobeNewswire September 11, 2025 NPI-001 shows more than 50% reduction in photoreceptor loss caused by RP associated with USH over two years NPI-001 was well tolerated, with no persistent drug-related adverse events Results were leveraged to design […]